Normally, I look forward to meeting as many shareholders as I can in person, but these are unusual times. I am pleased to report that I have been impressed by what I have seen since assuming the CEO role. In addition, other operating uses of cash include a reduction in accounts payable of approximately $799,000, more than offset by non-cash items including stock compensation expense of approximately $2.5 million, and expense recorded for the issuance of stock for services, amortization of right-of-use asset, and depreciation of approximately $1.4 million.Net cash from financing activities for the three months ended September 30, 2020 was approximately $28.6 million, compared to a use of cash of approximately $1,400 for the three months ended September 30, 2019, an increase of approximately $28.6 million. We intend to pursue a hybrid sales model for the United States utilizing a small number of high-quality regional distributors who will be supported in the field by our own Zomedica direct sales employees, some of whom will service key geographies independently of our distributors. Cohen joined Zomedica in June of 2020 following successfully serving as President and Chief Executive Officer at a series of early stage medical device and biotechnology companies.Â Prior to his 20 years in the CEO position, he was a member of senior management at large multinationals including St. Jude Medical, Inc., Sulzermedica, and Pfizer Inc.Mr. Mr. Cohen brings a successful track record in developing and launching products in both the medical devise and biotechnology space, as well as managing and growing early stage healthcare-related companies.Â Â * In July 2020, the Company completed a $30.0 million offering of common shares and warrants. Zomato on Tuesday said it has acquired the Indian business of Uber Eats in an all-stock … Â Â * In May 2020, the Company completed a $20.0 million offering of common shares and warrants. With a team that includes clinical veterinary professionals, it is Zomedicaâs mission to provide veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY CIRCULAR/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SHAREHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED DOMESTICATION. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. At the Meeting, the Companyâs shareholders approved the following proposals: * Election of Jeffrey Rowe, Robert Cohen, Johnny D. Powers, Rodney Williams, Chris MacLeod and Christopher Wolfenberg as directors; * Appointment of MNP LLP as the auditors of the Company and related matters; * Authorization of a reduction of the stated capital account applicable to the Common Shares of the Company in the discretion of the board of directors; * An amendment to the articles of the Company (the âArticlesâ) to remove a lien on a share registered in the name of a shareholder for a debt to the Company; * An amendment to the Articles allowing for shareholder meetings to be held outside of Alberta; * An amendment to the Articles to change the name of the Company from âZomedica Pharmaceuticals Corp.â to âZomedica Corp.â; and, * The ratification and confirmation of amendments to the Companyâs by-laws. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and pilot and pivotal studies, uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon Zomedicaâs business operations generally, including Zomedicaâs ability to develop its diagnostic products,Â and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Ms. Cotter has served as the Vice President of Finance for Zomedica from August of 2018, where she has taken a lead role in the internal accounting operations, as well as budgeting and forecasting responsibilities for the Company.Â She has held various consulting, controllership and CFO roles for both private and publicly held companies and has public accounting experience in both audit and tax services. As a vet myself, I know the value of such a product to a veterinary practice. Zomedicaâs product portfolio will include innovative diagnostics and therapeutics that emphasize patient health and practice health. Zomedicaâs product portfolio will include innovative diagnostics and therapeutics that emphasize patient health and practice health. Â© 2020 Verizon Media. With a team that includes clinical veterinary professionals, it is Zomedicaâs mission to provide veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. Info Edge Share Price, Info Edge Stock Price, Info Edge India Ltd. Stock/Share prices, Info Edge India Ltd. Live BSE/NSE, F&O Quote of Info Edge India Ltd. with Historic price charts for NSE / BSE. The increase was due to additional legal fees associated with the COVID-19 pandemic disclosures, our offering activity and the appointment of our new Interim Chief Executive Officer.Â Professional fees for the six months ended June 30, 2020 were $573,472 compared to $989,946 for the six months ended June 30, 2019, a decrease of $416,474 or 42%. The decrease resulted primarily from a lower net loss for the nine months ended September 30, 2020 compared to the comparable period of 2019. Zomedica Pharmaceuticals Corp.Â (NYSE American: ZOM) (âZomedicaâ or the âCompanyâ), a veterinary diagnostic company, announced today that it has completed the verification of TRUFORMAâ¢, its point-of-care diagnostic biosensor platform, and the first assay, Canine total T4 (âtT4â) thyroxine. "Zomedica is in the process of building its sales organization in preparation for commercial launch. The entire organization will be supported by MyZomedica, the Companyâs online portal, which will streamline customer communication and digital touchpoints, giving access to the Zomedica support team and resources. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Stay safe and healthy, and I look forward to delivering additional updates as we make further progress with our key milestones.Best regards,Robert CohenAbout ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.
Tru Roots Recipes, Biology Research Jobs Salary, Cajun Seasoning Brands, Industrial Engineering Pe Exam, Husqvarna 128ld Fuel Line Size, Freshwater Goby Tank Size, Northern Rough-winged Swallow Eggs, Define Neighbor In The Bible, Husqvarna 115il Ireland,